CALCIMEDICA INC (CALC)

Company Profile

CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Its technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. Its lead product candidate, Auxora, is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is developed for use in patients with acute inflammatory and immunologic illnesses. Auxora is evaluated in a Phase IIb trial for AP with accompanying SIRS, called CARPO; a phase I/II trial called CRSPA being conducted in pediatric patients with AIPT as a side effect of pediatric acute lymphoblastic leukemia treatment with asparaginase; and a phase II dose-ranging pharmacodynamic study in critical COVID-19 patients.

Company Info

CALCIMEDICA INC

505 Coast Boulevard South, Suite 307

La Jolla CALIFORNIA

P: 18589525500

Employees: 8

Website: https://calcimedica.com/